Generate Biomedicines (NASDAQ:GENB) Announces Earnings Results

Generate Biomedicines (NASDAQ:GENB) posted its earnings results on Thursday. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.59), Zacks reports.

Generate Biomedicines Stock Up 0.5%

GENB stock traded up $0.07 during midday trading on Friday, reaching $13.66. 291,612 shares of the company’s stock traded hands, compared to its average volume of 465,861. Generate Biomedicines has a fifty-two week low of $11.00 and a fifty-two week high of $15.89. The stock’s 50-day simple moving average is $12.62.

Analyst Upgrades and Downgrades

GENB has been the topic of several analyst reports. Cantor Fitzgerald initiated coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating on the stock. Piper Sandler assumed coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price objective on the stock. Morgan Stanley assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $20.00 target price on the stock. Guggenheim initiated coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Zacks Research upgraded Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Generate Biomedicines currently has an average rating of “Moderate Buy” and an average target price of $25.00.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.